Ozdemir V - Search Results

1

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. Ozdemir V, et al. Pharmacogenetics. 2000 Jul;10(5):373-88. doi: 10.1097/00008571-200007000-00001. Pharmacogenetics. 2000. PMID: 10898107

2

The science of pharmacological variability: an essay.

Kalow W, Ozdemir V, Tang BK, Tothfalusi L, Endrenyi L. Kalow W, et al. Among authors: ozdemir v. Clin Pharmacol Ther. 1999 Nov;66(5):445-7. doi: 10.1016/S0009-9236(99)70006-8. Clin Pharmacol Ther. 1999. PMID: 10579470 No abstract available.

3

What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

Ozdemir V, Shear NH, Kalow W. Ozdemir V, et al. Drug Saf. 2001;24(2):75-85. doi: 10.2165/00002018-200124020-00001. Drug Saf. 2001. PMID: 11235820 Review.

4

CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.

Ozdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK, Albers LJ, Reist C, Roy R, Walkes W, Afra P. Ozdemir V, et al. J Clin Psychopharmacol. 2001 Aug;21(4):398-407. doi: 10.1097/00004714-200108000-00007. J Clin Psychopharmacol. 2001. PMID: 11476124 Clinical Trial.

5

CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.

Aklillu E, Kalow W, Endrenyi L, Harper P, Miura J, Ozdemir V. Aklillu E, et al. Among authors: ozdemir v. Pharmacogenet Genomics. 2007 Nov;17(11):989-93. doi: 10.1097/FPC.0b013e3282f01aa3. Pharmacogenet Genomics. 2007. PMID: 18075468 Clinical Trial.

6

Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.

Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W. Ozdemir V, et al. J Clin Psychopharmacol. 1998 Jun;18(3):198-207. doi: 10.1097/00004714-199806000-00004. J Clin Psychopharmacol. 1998. PMID: 9617978

7

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.

Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P, Widén J, Svensson JO, Albers LJ, Kennedy JL, Endrenyi L, Kalow W. Ozdemir V, et al. Pharmacogenet Genomics. 2007 May;17(5):339-47. doi: 10.1097/FPC.0b013e32801a3c10. Pharmacogenet Genomics. 2007. PMID: 17429316 Clinical Trial.

8

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Ozdemir V, et al. Clin Pharmacol Ther. 1997 Sep;62(3):334-47. doi: 10.1016/S0009-9236(97)90037-0. Clin Pharmacol Ther. 1997. PMID: 9333110 Clinical Trial.

9

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, Kennedy JL. Basile VS, et al. Among authors: ozdemir v. Mol Psychiatry. 2000 Jul;5(4):410-7. doi: 10.1038/sj.mp.4000736. Mol Psychiatry. 2000. PMID: 10889552

10

Toward Panvigilance for Medicinal Product Regulation: Clinical Trial Design Using Extremely Discordant Biomarkers.

Özdemir V, Endrenyi L. Özdemir V, et al. OMICS. 2019 Mar;23(3):131-133. doi: 10.1089/omi.2019.0013. Epub 2019 Feb 21. OMICS. 2019. PMID: 30789303 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

209 results

Search Page